| Background | Tarextumab, is a fully human mAb that inhibits ligand-dependent signaling through both Notch2 and Notch3. Tarextumab was tested in a range of xenograft models and found to be active in breast, ovarian, lung, and pancreatic tumors. Administration of tarextumab delayed tumor recurrence after chemotherapeutic treatment and reduced tumor-initiating cell frequency, particularly in combination with chemotherapy. Mechanism of action studies indicated that tarextumab blocked Notch signaling in both tumor and stromal cells and induced differentiation of tumor cells. In the stromal cells, tarextumab inhibited gene expression required for the function of pericytes, vascular support cells essential for tumor angiogenesis. |
|---|
